Temozolomide chemotherapy in recurrent oligodendroglioma

Neurology

Volumn 57, Issue 2, 2001, Pages 340-342

  Van Den Bent, M J ^a,b   Keime Guibert, F ^c   Brandes, A A ^d   Taphoorn, M J B ^e   Kros, J M ^b   Eskens, F A L M ^b   Carpentier, A F ^f  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0035943074     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.2.340     Document Type: Article

References (10)

1. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy
2. Chemotherapy for anaplastic oligodendroglioma
3. Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggresive oligodendroglioma
4. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
5. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
6. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
7. Salvage chemotherapy for oligodendroglioma
8. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas
9. Role of chemotherapy in oligodendroglial tumors: A review of the experience at the University of Torino
10. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma